As reported by OA Online, Origenis has entered into a global license deal with Expansion Therapeutics. The two will collaborate on research small molecule discovery initiatives targeting RNA-mediated diseases. The two will launch a lead optimization program leveraging the Origenis artificial intelligence (AI) discovery platform to identify drug development candidates for Expansion’s portfolio of RNA-targeted small molecule medicines. Expansion will leverage Origenis proprietary AI drug discovery platform MolMind® and the Moresystem® in conjunction with other innovative embedded technologies.
Who is Oregenis and Expansion Therapeutics? Origenis GmbH, founded in 2005, is a privately-held German biopharmaceutical company developing brain-penetrating highly selective small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases. Origenis leverages its unique capabilities in drug design, compound synthesis and characterization to engineer a continuous stream of proprietary IP-protected new chemical entities capable of permeating the blood-brain barrier. Origenis’ approach has been validated by multiple partners resulting in a significant IP and R&D portfolio that ensures strong patent protection.
Expansion Therapeutics, founded in 2016, has raised over $55 million in just a couple years. Based in San Diego, California, they are a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.